CR20130181A - UNA COMPOSICIÓN QUE COMPRENDE 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] Y CROSCARMELOSA SODICA - Google Patents
UNA COMPOSICIÓN QUE COMPRENDE 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] Y CROSCARMELOSA SODICAInfo
- Publication number
- CR20130181A CR20130181A CR20130181A CR20130181A CR20130181A CR 20130181 A CR20130181 A CR 20130181A CR 20130181 A CR20130181 A CR 20130181A CR 20130181 A CR20130181 A CR 20130181A CR 20130181 A CR20130181 A CR 20130181A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methylpropanothioate
- ethylbutyl
- cyclohexyl
- carbonyl
- phenyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
- 229910052708 sodium Inorganic materials 0.000 title 1
- 239000011734 sodium Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una formulación basada en una matriz higroscópica, a un proceso para la fabricación de la misma y a su utilización para el tratamiento de enfermedades.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10190045 | 2010-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20130181A true CR20130181A (es) | 2013-05-29 |
Family
ID=43759428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20130181A CR20130181A (es) | 2010-11-04 | 2013-04-24 | UNA COMPOSICIÓN QUE COMPRENDE 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] Y CROSCARMELOSA SODICA |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9107836B2 (es) |
| EP (1) | EP2635263B1 (es) |
| JP (1) | JP5676005B2 (es) |
| KR (1) | KR101579659B1 (es) |
| CN (2) | CN103200935A (es) |
| AR (1) | AR083693A1 (es) |
| BR (1) | BR112013010704B8 (es) |
| CA (1) | CA2815280C (es) |
| CL (1) | CL2013001164A1 (es) |
| CR (1) | CR20130181A (es) |
| EA (1) | EA025649B1 (es) |
| EC (1) | ECSP13012603A (es) |
| ES (1) | ES2553279T3 (es) |
| IL (1) | IL225780B (es) |
| MA (1) | MA34643B1 (es) |
| MX (1) | MX345650B (es) |
| MY (1) | MY164729A (es) |
| NZ (1) | NZ609529A (es) |
| PE (1) | PE20140018A1 (es) |
| PH (1) | PH12013500864A1 (es) |
| SG (1) | SG190025A1 (es) |
| TW (1) | TWI507192B (es) |
| UA (1) | UA110117C2 (es) |
| WO (1) | WO2012059447A1 (es) |
| ZA (1) | ZA201302954B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8293727B2 (en) | 2009-02-10 | 2012-10-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| BR112015024116A2 (pt) | 2013-03-27 | 2017-10-24 | Hoffmann La Roche | marcadores genéticos para prever capacidade de resposta à terapia |
| JP5871984B2 (ja) * | 2013-04-15 | 2016-03-01 | 株式会社三和化学研究所 | オルメサルタンメドキソミルを含有する医薬組成物 |
| RU2016127357A (ru) | 2013-12-19 | 2018-01-24 | Ф. Хоффманн-Ля Рош Аг | Модулятор сетр для применения в лечении заболеваний глаз |
| JP6854752B2 (ja) | 2014-07-30 | 2021-04-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー |
| CN104434913A (zh) * | 2014-12-20 | 2015-03-25 | 长沙佰顺生物科技有限公司 | 一种安塞曲匹药物组合物及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| US7208465B2 (en) * | 2000-11-03 | 2007-04-24 | The Procter & Gamble Company | Methods and compositions for improved fragrancing of a surface |
| CA2509688A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| PL1603553T3 (pl) * | 2003-03-17 | 2012-04-30 | Japan Tobacco Inc | Kompozycje farmaceutyczne inhibitorów CETP |
| CA2519458A1 (en) | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| MXPA06001506A (es) * | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa. |
| DE602006004558D1 (de) | 2005-01-28 | 2009-02-12 | Pfizer Prod Inc | Schnell zerfallendes mikroporöses bindemittel und herstellungsverfahren dafür |
| US7435849B2 (en) | 2005-10-31 | 2008-10-14 | Hoffmann-La Roche Inc. | Process for the production of acid chlorides |
| EP1935867A1 (en) | 2006-12-20 | 2008-06-25 | F. Hoffmann-La Roche Ag | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid |
| AU2009326326B2 (en) * | 2008-12-08 | 2015-05-21 | F. Hoffmann-La Roche Ag | Combined drug administration |
| US20110004011A1 (en) | 2009-07-01 | 2011-01-06 | Declan Costello | Novel process |
-
2011
- 2011-10-31 KR KR1020137014214A patent/KR101579659B1/ko active Active
- 2011-10-31 PE PE2013000910A patent/PE20140018A1/es not_active Application Discontinuation
- 2011-10-31 CA CA2815280A patent/CA2815280C/en active Active
- 2011-10-31 MY MYPI2013700710A patent/MY164729A/en unknown
- 2011-10-31 PH PH1/2013/500864A patent/PH12013500864A1/en unknown
- 2011-10-31 UA UAA201306203A patent/UA110117C2/uk unknown
- 2011-10-31 CN CN2011800532370A patent/CN103200935A/zh active Pending
- 2011-10-31 EP EP11776201.3A patent/EP2635263B1/en active Active
- 2011-10-31 BR BR112013010704A patent/BR112013010704B8/pt active IP Right Grant
- 2011-10-31 SG SG2013032123A patent/SG190025A1/en unknown
- 2011-10-31 JP JP2013537093A patent/JP5676005B2/ja active Active
- 2011-10-31 ES ES11776201.3T patent/ES2553279T3/es active Active
- 2011-10-31 WO PCT/EP2011/069087 patent/WO2012059447A1/en not_active Ceased
- 2011-10-31 MX MX2013004584A patent/MX345650B/es active IP Right Grant
- 2011-10-31 EA EA201390622A patent/EA025649B1/ru not_active IP Right Cessation
- 2011-10-31 NZ NZ609529A patent/NZ609529A/en unknown
- 2011-10-31 CN CN201610309140.6A patent/CN105833283A/zh active Pending
- 2011-11-03 US US13/288,082 patent/US9107836B2/en active Active
- 2011-11-03 AR ARP110104077A patent/AR083693A1/es unknown
- 2011-11-03 TW TW100140194A patent/TWI507192B/zh not_active IP Right Cessation
-
2013
- 2013-04-15 IL IL225780A patent/IL225780B/en active IP Right Grant
- 2013-04-23 ZA ZA2013/02954A patent/ZA201302954B/en unknown
- 2013-04-24 CR CR20130181A patent/CR20130181A/es unknown
- 2013-04-29 CL CL2013001164A patent/CL2013001164A1/es unknown
- 2013-05-03 MA MA35868A patent/MA34643B1/fr unknown
- 2013-05-03 EC ECSP13012603 patent/ECSP13012603A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6480979A2 (es) | Inhibidores de bace | |
| CR20130181A (es) | UNA COMPOSICIÓN QUE COMPRENDE 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] Y CROSCARMELOSA SODICA | |
| CO6430430A2 (es) | Compuestos para la reduccion de produccionn de beta-amiloide | |
| BRPI0721905B8 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
| CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
| EP3586631A3 (en) | Plant health composition | |
| CO6531500A2 (es) | Composiciones y metodos para el tratamiento de la xerostomia | |
| CO6420352A2 (es) | Composiciones pesticidas | |
| BR112015012918A2 (pt) | composições para cuidado oral contendo zinco e fluoreto estável | |
| UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
| UA109547C2 (uk) | Композиція для боротьби з захворюванням рослин і спосіб боротьби з захворюванням рослин | |
| MX366925B (es) | Inhibidores de ibat para el tratamiento de enfermedades hepaticas. | |
| ME01456B (me) | Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola | |
| BR112015031913A2 (pt) | processo para a fabricação de amino-benzoxazinonas 4-propargilatadas e sua utilização | |
| CO6351777A2 (es) | Compuestos de tetraciclina sustituidod con fluor en c7 | |
| JO3493B1 (ar) | صيغ صيدلانية | |
| CL2012002560A1 (es) | Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7). | |
| MX391620B (es) | Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). | |
| MX2015016971A (es) | Formulacion que comprende un agente hipolipidemico. | |
| MX2010005007A (es) | Composiciones y metodos para el tratamiento de la xerostomia. | |
| BR112014014877A2 (pt) | derivados da 1,5-naftiridina e inibidores do melk contendo os mesmos | |
| CL2011001405A1 (es) | Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina. | |
| BR112012007798A2 (pt) | microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas | |
| NI200900207A (es) | Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas. | |
| MX2013008699A (es) | Compuestos para reducir la produccion de beta-amiloide. |